Terms: = Liver cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
175 results:
1. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based car-T technology.
Lin K; Xia B; Wang X; He X; Zhou M; Lin Y; Qiao Y; Li R; Chen Q; Li Y; Feng J; Chen T; Chen C; Li X; Zhang H; Lu L; Liu B; Zhang X
J Transl Med; 2024 Apr; 22(1):349. PubMed ID: 38610029
[TBL] [Abstract] [Full Text] [Related]
2. Diindoles produced from commensal microbiota metabolites function as endogenous car/Nr1i3 ligands.
Liu J; Malekoltojari A; Asokakumar A; Chow V; Li L; Li H; Grimaldi M; Dang N; Campbell J; Barrett H; Sun J; Navarre W; Wilson D; Wang H; Mani S; Balaguer P; Anakk S; Peng H; Krause HM
Nat Commun; 2024 Mar; 15(1):2563. PubMed ID: 38519460
[TBL] [Abstract] [Full Text] [Related]
3. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted car-T cell therapy: a case report.
Zhong G; Zhang X; Guo Z; Gao Y; Zhao B; Liu X; Chen L; Qiao J; Yu C; Wang L; Li Y; Yu L
Front Immunol; 2024; 15():1325860. PubMed ID: 38487523
[TBL] [Abstract] [Full Text] [Related]
4. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular carcinoma: Where Do We Stand?
Aggeletopoulou I; Kalafateli M; Triantos C
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473878
[TBL] [Abstract] [Full Text] [Related]
5. Mesothelin car T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract] [Full Text] [Related]
6. γδ T Cells: A Game Changer in the Future of Hepatocellular carcinoma Immunotherapy.
Papadakos SP; Arvanitakis K; Stergiou IE; Koutsompina ML; Germanidis G; Theocharis S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338658
[TBL] [Abstract] [Full Text] [Related]
7. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [
Trautwein NF; Schwenck J; Seitz C; Seith F; Calderón E; von Beschwitz S; Singer S; Reischl G; Handgretinger R; Schäfer J; Lang P; Pichler BJ; Schulte JH; la Fougère C; Dittmann H
Theranostics; 2024; 14(3):1212-1223. PubMed ID: 38323317
[No Abstract] [Full Text] [Related]
8. Recent Progress in Systemic Therapy for Advanced Hepatocellular carcinoma.
Sadagopan N; He AR
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279258
[TBL] [Abstract] [Full Text] [Related]
9. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
10.
Sun C; Li D; Wang Z
Immunotherapy; 2024 Mar; 16(5):331-340. PubMed ID: 38264838
[TBL] [Abstract] [Full Text] [Related]
11. Interaction with YAP underlies the species differences between humans and rodents in car-dependent hepatocyte proliferation.
Shizu R; Makida N; Sobe K; Ishimura M; Takeshita A; Hosaka T; Kanno Y; Sasaki T; Yoshinari K
Toxicol Sci; 2024 Feb; 198(1):101-112. PubMed ID: 38128062
[TBL] [Abstract] [Full Text] [Related]
12. GPC3-IL7-CCL19-car-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
[TBL] [Abstract] [Full Text] [Related]
13. Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment.
He X; Lan H; Jin K; Liu F
Front Immunol; 2023; 14():1237764. PubMed ID: 37790928
[TBL] [Abstract] [Full Text] [Related]
14. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.
Mak JWY; Law AWH; Law KWT; Ho R; Cheung CKM; Law MF
World J Gastroenterol; 2023 Sep; 29(33):4942-4961. PubMed ID: 37731995
[TBL] [Abstract] [Full Text] [Related]
15. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the carTITUDE-1 Study.
Htut M; Dhakal B; Cohen AD; Martin T; Berdeja JG; Usmani SZ; Agha M; Jackson CC; Madduri D; Deraedt W; Zudaire E; Yeh TM; Xu X; Pacaud L; Akram M; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):882-888. PubMed ID: 37716872
[TBL] [Abstract] [Full Text] [Related]
16. Spleen SORT LNP Generated in situ car T Cells Extend Survival in a Mouse Model of Lymphoreplete B Cell Lymphoma.
Álvarez-Benedicto E; Tian Z; Chatterjee S; Orlando D; Kim M; Guerrero ED; Wang X; Siegwart DJ
Angew Chem Int Ed Engl; 2023 Oct; 62(44):e202310395. PubMed ID: 37651468
[TBL] [Abstract] [Full Text] [Related]
17. Targeted delivery of a PD-1-blocking scFv by CD133-specific car-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma.
Yang C; You J; Pan Q; Tang Y; Cai L; Huang Y; Gu J; Wang Y; Yang X; Du Y; Ouyang D; Chen H; Zhong H; Li Y; Yang J; Han Y; Sun F; Chen Y; Wang Q; Weng D; Liu Z; Xiang T; Xia J
BMC Med; 2023 Aug; 21(1):327. PubMed ID: 37635247
[TBL] [Abstract] [Full Text] [Related]
18. Bibliometric study of immunotherapy for hepatocellular carcinoma.
Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
[TBL] [Abstract] [Full Text] [Related]
19. Application of adoptive cell therapy in hepatocellular carcinoma.
Wu D; Li Y
Immunology; 2023 Dec; 170(4):453-469. PubMed ID: 37435926
[TBL] [Abstract] [Full Text] [Related]
20. HGF-Based car-T Cells Target Hepatocellular carcinoma Cells That Express High Levels of c-Met.
Ma H; Wei W; Liang D; Xu X; Yang D; Wang Q; Wang Y; Wei Q; Sun B; Zhao X
Immunol Invest; 2023 Nov; 52(6):735-748. PubMed ID: 37409941
[TBL] [Abstract] [Full Text] [Related]
[Next]
